OBJECTIVES: Immune therapy targeting cancer/testis (CT) antigens improve the survival in several types of solid tumours. The expression of CT antigens is related to poor survival in non-small-cell lung cancer (NSCLC). The epidermal growth factor receptor (EGFR) mutation is the best predictive factor for the sensitivity to tyrosine kinase inhibitors in lung adenocarcinoma. The aim of this study was to elucidate the correlation between the expression of CT antigens and clinicopathological factors, including the EGFR mutation, and to analyse the prognosis in lung adenocarcinoma.
INTRODUCTION
Immunotherapy against solid tumours is an attractive therapeutic strategy [1] [2] [3] [4] [5] . Small et al. [1] reported the result of a randomized phase 3 trial in which Spilucel T (APC8015) improved the survival in hormone refractory prostate cancer. A phase 3 trial to test the efficacy of the anticancer vaccination in advanced melanoma patients demonstrated that the patients treated by the concomitant therapy with gp100 vaccination and high-dose IL-2 therapy have better survival than those treated by IL-2 alone [2] . Robert et al. [3] reported that ipilimumab, which can block cytotoxic T-lymphocyte-associated antigen 4, could improve the survival in previously treated melanoma patients.
Vansteenkiste et al. [4] reported a phase 2 study of adjuvant therapy with the melanoma-associated antigen gene (MAGE)-A3 in patients with completely resected stage IB or II non-small-cell lung cancer (NSCLC), which could achieve a 43% reduction in the relative risk of relapse in comparison with placebo, and a randomized, double-blind phase III study known as MAGRIT (MAGE-A3 as adjuvant NSCLC immunotherapy) trial has been initiated [5] .
Specific immune therapy requires the selection of a suitable tumour-associated antigen (TAA). Suitable conditions such as TAA for immunotherapy would be specific and stable expression by tumours, and no expression in normal tissues. Cancer/testis (CT) antigens are expressed specifically in cancer cells except for the testis or placenta, which do not express human leukocyte antigen (HLA) class I among normal tissues. The expression of at least one of the CT antigens negatively affects the survival of patients with NSCLC [6] . MAGE-A4 expression was detected more frequently in males or squamous cell carcinoma more than in female or adenocarcinoma.
Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor has shown a clinical response in a significant proportion of patients with an EGFR-activating mutation [7] [8] [9] [10] . Such EGFR-activating mutations occur more frequently in females, nonsmokers, Asians and adenocarcinoma than in their counterparts [11] . Oestrogen receptor beta (Erβ) expression or the HLA-A2 allele is associated with the EGFR mutate status [11] . The predisposition of patients with the EGFR-activating mutation suggested the hypothesis that the expression of CT antigens might be related to the EGFR mutation status. This study analysed the expression of CT antigens and EGFR mutation in lung adenocarcinoma and estimated their relationship.
MATERIALS AND METHODS

Patients
Patients provided written informed consent to participate in this study and to donate blood. The institutional review board approved informed consent for the use of the tumour specimens was obtained either from all the patients or from the patient's legal guardians.
Data were collected from a total of 281 lung adenocarcinoma patients who underwent surgery at the University of Occupational and Environmental Health, Japan, between January 2001 and August 2006. The specimens from 125 cases (44%) were too small to extract sufficient DNA and/or RNA, so they were excluded from this analysis, in addition to 2 cases (0.7%) with the coexistence of another histological lung cancer. A total of 154 patients (55%) were reviewed in the analysis.
All resected specimens underwent a pathological examination, and the pathological TNM stage was classified according to the 7th edition of the TNM classification described by the International Association for the Study of Lung Cancer; however, the study used Naruke's lymph node map [12] . The patients were followed-up every month during the first post-operative year and at approximately 2-to 4-month intervals thereafter. The evaluations included a physical examination, chest roentgenography, an analysis of blood chemistry and measurement of tumour markers. Chest and abdominal CT, brain magnetic resonance imaging and a bone scintiscan were performed every 6 months for 5 years after surgery. Additional examinations were performed if any symptoms or signs of recurrence were detected.
Evaluation of cancer/testis antigens expression
The analysis of CT antigens expression was described previously [6] . Briefly, the cDNA converted from the extracted RNA of each tumour served as a template for PCR. Gene-specific primers were used; β-actin-(internal control) specific primer (forward primer, 5-GGC ATC GTG ATG GAC TCC G-3 and reverse primer, 5-GCT GGA AGG TGG ACA GCG A-3), MAGE-A4-specific primer (forward primer, 5-GAG CAG ACA GGC CAA CCG-3 and reverse primer, 5-AAG GAC TCT GCG TCA GGC-3) and KK-LC-1-specific primer (forward primer, 5-ATG AAC TTC TAT TTA CTC CTA GCG AGC-3 and reverse primer, 5-TTA GGT GGA TTT CCG GTG AGG-3). The tumour was positive for any CT antigens expression if at least one of MAGE-A4 or KK-LC-1could be detected.
Epidermal growth factor receptor mutation analysis
The detection of the EGFR-activating mutation was described previously [11] . Briefly, genomic DNA was extracted and purified from either fresh frozen tumours or tumours embedded in paraffin blocks. The two most common EGFR mutations, the in-frame deletion in exon 19 and L858R point mutation in exon 21, were evaluated by using the PCR screening method. The gene-specific primers were exon 19 (forward primer, 5-GTC TTCCTTCTCTCTCTGTCATAG-3 and reverse primer, 5-CCACACA GCAAAGCAGAAACTCAC-3). Two different forward primers were used for the detection of L858R point mutation in exon 21; wild type (5-TCAAGATCACAGATTTTGGGCT-3) and L858R point mutation (5-TCAAGATCACAGATTTTGGGCG-3). The reverse primer for both the wild type and mutant type was 5-CATCCTCCCC TGCATGTGTTAAAC-3. Positive and negative controls for EGFR mutations were confirmed by a direct sequencing method.
Evaluation of Erβ expression
The method of immunohistochemical staining of Erβ and the evaluation of the expression were previously described [11] . Briefly, paraffin-embedded specimens were labelled by anti-Erβ antibody (Santa Cruz Biotechnology, CA, USA) and stained using the Envision kit (DAKO, Kyoto, Japan). The stained specimens were categorized into eight degrees according to the immunohistochemical scores reported [11] . Initially, six degrees of proportional score for positive staining were assigned according to the proportion of positive tumour cells (0, none; 1, <1/100; 2, 1/100 to 1/10; 3, 1/10 to 1/3; 4, 1/3 to 2/3 and 5, >2/3). Four degrees of intensity score were assigned according to the intensity of staining (0, none; 1, weak; 2, intermediate and 3, strong). The proportion and intensity scores were then added together to obtain a total score, which ranged from 0 to 8. The Erβ expression of the tumour was categorized as a negative/weak expression when the score was 0-4, and a strong expression when the score was 5-8. The slides were independently examined by two observers who were blinded to the clinicopathological data. When a discrepancy was found between them, a consensus was reached via their simultaneous examination using a doubleheaded microscope.
Statistical analysis
The two groups were compared using the χ 2 test, and multivariate models were constructed using logistic regression including the confounding factors with a P-value <0.2 in the univariate analysis. The overall survival (OS) was calculated from the day of the surgery to the known date of death according to hospital medical records. The disease-free survival (DFS) was defined as the time from the operation to the first event of either recurrence of disease or death. The cancer-related death was defined as the time from the operation to the date of the cancer death. The radiology reports and physical examination were used to determine the date of recurrence. The patient was censored for DFS on the last date on which the medical records were available if the medical records did not show any evidence of recurrence or death. The OS and DFS were measured for each patient from the day of surgical treatment. The survival curves were estimated using the Kaplan-Meier method, and differences among them were evaluated by the log-rank test. The univariate and multivariate analyses were used to assess the effect of covariates on the OS and DFS and were performed using the Cox proportional hazard model. A value of P < 0.05 was considered to be significant. The R statistical package (www.r-project.org) was used for all of the analyses.
RESULTS
The EGFR-activating mutation was detected in 64 of 154 (42%) adenocarcinoma patients. Twenty-nine patients (14%) had the deletion in exon 19, 35 (23%) had the point mutation in exon 21 and 1 (0.6%) had both. The relationships between the EGFR mutation and other clinicopathological findings are shown in Table 1 . The EGFR mutation was detected more often in females, smokers and well-differentiated adenocarcinomas (G1). The mutation cases showed significantly more strong Erβ expression, as previously reported [13] .
The PCR amplification of CT antigen genes showed that the gene expression of MAGE-A4 could be detected in 14 (9%) and KK-LC-1 in 54 (35%) patients. Therefore, eight tumours had both. MAGE-A4 or KK-LC-1 could be found more often in the EGFR wild-type population (P = 0.03 and 0.01, respectively) and the negative expression of any CT antigens was associated with the EGFR mutation (P < 0.01). The expression of other CT antigens (MAGE-A3 and NY-ESO-1) was analysed, but they were not statistically associated with the EGFR mutation. HLA-A2 status, which was previously reported to be a predictor for the EGFR mutation in female adenocarcinoma patients could not be proven to be associated with the EGFR mutation status in this limited population (P = 0.33).
A multivariate analysis of clinicopathological factors and the EGFR mutation demonstrated that smokers, strong Erβ expression and negative of any CT expression were independently associated with the EGFR-activating mutation (P < 0.01; odds ratio 3.99, 95% confidence interval (CI) 1.33-13.3, P = 0.01; odds ratio 2.70, 95% CI 1.67-12.5 and P < 0.01; odds ratio 2.70, 95% CI 1.67-12.5), as shown in Table 2 . KK-LC-1 or MAGE-A4 expression could not be proven to be a predictive factor for EGFR status (P = 0.07; odds ratio 2.32, 95% CI 0.98-5.81 and P = 0.06, odds ratio 5.05, 95% CI 0.95-40.5, respectively) if the multivariate analysis was calculated by using their expression as a factor instead of any CT expression.
The relationships between the expression of CT antigens and clinical findings are shown in Table 3 . There was no significant difference in clinical characteristics associated with the expression of any CT antigens.
A survival analysis was performed in 135 patients with completely resected adenocarcinoma and 53 in those with a tumour expressing any of the CT antigens and 82 in those without the expression of the CT antigens ( Table 3 ). The 5-year OS rate after surgery in all adenocarcinoma patients was 78.5% and that of DFS was 72.2%. Figure 1 shows the survival curves of the OS (Fig. 1a) and DFS (Fig. 1a) in patients with tumours negative and positive for the expression of any CT antigens. The 5-year OS rate in the patients without CT antigens expression was 83.2% and that in patients with tumours expressing any CT antigens was 71.1%. The 5-year OS rate after surgery was significantly worse in patients having any CT antigens (P < 0.038). The 5-year DFS rate of the patients with negative for any CT antigens expression was 76.2%, and that of patients expressing any CT antigens were 65%, which were not significantly different (P = 0.16). Regarding the cancer-related death, 5-year survival rate after surgery in the patients with tumours expressing any CT antigen was 78.5% and that in the patients with tumours without CT antigens expression was 88.5%. However, there was no significant difference (P = 0.07). Figure 2 showed the OS curve in patients Including ever smoker and current smoker. The cases expressing MAGE-A4 and/or KK-LC-1. There is no significant difference between the two groups (P = 0.16). The joint effect of gender, smoking status, the pathological T factor, node metastatic status, EGFR mutate status, Erβ expression and any CT antigens expression was examined using a Cox regression analysis and only metastatic lymph node metastasis was a significant factor for predicting the prognosis (hazard ratio 2.92, 95% CI; 1.31-6.47, P = 0.009). The expression of any CT antigens could not be confirmed as a predictive factor for OS in the multivariate analysis (hazard ratio 0.73, 95% CI; 0.33-1.62, P = 0.43).
DISCUSSION
The current study showed that negative expression of any CT antigens was more frequent in adenocarcinoma patients with an EGFR mutation. Patients with MAGE-A4 expressing NSCLC show a poorer prognosis than patients without MAGE-A4 expression [6] . This study focussed on adenocarcinoma and confirmed that the adenocarcinoma patients with expression of any CT antigens had a poorer prognosis than those without expression of any CT antigens.
MAGE-A4 and KK-LC-1 are members of the CT antigen family and are not expressed in normal tissue except for the testis or placenta, which do not present HLA class I molecules. The expression of the CT antigen is almost specific for cancer. Sienel et al. [14] analysed the expression of MAGE genes in bone marrow as a marker for micrometastasis in NSCLC patients and reported that the expression of these genes is associated with a poor clinical outcome. MAGE-A4 is expressed in carcinoma in the oesophagus (63%), the head and neck (53%), the lung (51%) and the bladder (33%), and in metastatic melanomas (28%) [15] . MAGE-A4 expression is found in 20.1% of patients with NSCLC and 8.2% with adenocarcinoma. There is a high level of expression of MAGE-A4 when a tumour sample is found to be positive [15] . This indicates that the gene is an optimal candidate for a therapeutic target; the immune response of targeting MAGE-A4 has been investigated. The expression of MAGE-A4 is associated with a poor prognosis in NSCLC [6] . The status of the EGFR-activating mutation, which showed the exclusive relationship with the CT antigen expression, might be related to the prognosis. However, it has been reported that the CT antigen expression was related to cell cycle and proliferation [13, 16] , apoptosis [17] and susceptibility to cytokines in cancer cells [18] , and Including ever smoker and current smoker. b The cases expressing MAGE-A4 and/or KK-LC-1. Figure 1 : (a) The OS and (b) DFS curves in patients with tumours with negative and positive expression of any CT antigens. The OS was significantly better in cases negative for cancer testis antigens than patients having any CT (P < 0.04), but there were no significant differences in the DFS (P = 0.16).
then the CT antigen itself might be associated with the prognosis. It is possible that the therapeutic strategy against cells expressing MAGE-A4 could improve the NSCLC clinical outcome. KK-LC-1 was detected as a TAA and it is expressed in 9 of 18 (50%) NSCLC cell lines and in 32.6% of NSCLC tissues examined [19] . It is expressed relatively more often in adenocarcinoma (32.1%) in comparison with other CT antigens (8.2-17%) [6] . The gene coding KK-LC-1 is located on chromosome Xq22 and contains 113 amino acids. The function of this protein has not been clarified [19] . CD8+ cytotoxic lymphocytes with specific recognition against an antigenic KK-LC-1 peptide kills cancer cells expressing both KK-LC-1 and HLA-B*1507/1501 [19] . Moreover, we could show that adoptive transfer of the KK-LC-1 targeting cells in a mice model resulted in marked growth suppression of xenotransplanted tumours [20] . This indicates that KK-LC-1 could be a promising candidate for an antitumor target.
The activating mutation in the EGFR gene is strongly associated with a clinical response to tyrosine kinase inhibitors [7] [8] [9] [10] . A previous report showed that 77% of adenocarcinoma with the activating EGFR mutation show sensitivity to gefitinib, on the other hand, no cases with wild-type EGFR showed a clinical response [10] . Fukuoka et al. [21] recently demonstrated no difference in the OS between gefitinib and first line carboplatin/ paclitaxel in adenocarcinoma patients with/without an activating EGFR mutation, however, they showed that the EGFR mutations are the strongest predictive biomarker for progression-free survival and tumour response to gefitinib. The present data indicated that lung adenocarcinoma patients without an EGFR-activating mutation that express CT antigens could be candidates for immune therapy targeting CT antigens.
There is no direct association between EGFR mutations and carcinogens or molecules that affect the EGFR mutation susceptibility in adenocarcinoma patients. Some reports suggest that genetic susceptibility to DNA repair defects could predispose certain individuals to the development of EGFR mutant tumours [22] . The mutation in the 3-untranslated region of EGFR has thus been shown to result in an overexpression of EGFR through enhanced EGFR mRNA stability [23] . The functional association between CT antigen expression and the EGFR mutation was unclear; however, recent studies have demonstrated that CT antigens are involved in the regulation of transcription. CT antigen expression may affect transcription or cell signalling in adenocarcinoma, and also be related to EGFR gene instability. Some investigators have reported that the EGFR-activating mutation shows the exclusive relationship with the v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog mutation and anaplasticlymphomakinase fusion [24] . Therefore, we should investigate the relationship between the CT antigen expression and the genetic changes in lung cancer cells.
The current results provided more accurate knowledge about the CT antigens and the EGFR mutation. Two different therapeutic targets, the EGFR mutation and CT antigen expression, have a negative relationship with each other, and this may contribute to future therapeutic strategy in lung adenocarcinoma. The OS curve in patients with tumours with EGFR mutation/wild and positive/negative expression of any CT antigen. There were no significant difference in OS between patients with EGFR mutation and negative for CT antigen expression and patients with EGFR wild and positive for CT antigen expression (P = 0.16).
